NCT00594126View on ClinicalTrials.gov

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

Imetelstat Sodium (GRN163L)

25% dose escalation infused over 2 hours weekly

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Geron Corporation
All Listed Sponsors
lead

Geron Corporation

INDUSTRY